Robert Bruce is listed as an executive officer on 2 SEC Form D filings by 1 issuer between Jan 2022 and Jan 2023: Soricimed Biopharma Inc. (Moncton, New Brunswick, Canada (as filed: A3) — biotechnology — 2022–2023; $2.78M reported sold to 45 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Camille Belliveau (2 shared filings), Jack Stewart (2 shared filings), Marc Rubin (2 shared filings), Paul Gunn (2 shared filings), Susan Hicks (2 shared filings) and 2 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Robert Bruce and found 8 differences, 1 worth asking the sponsor about: Form D filed 192 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.